The effect of olfactory bulbectomy in the rat, alone or in combination with antidepressants and endogenous factors, on immune function

Human Psychopharmacology: Clinical and Experimental

Volumn 10, Issue 1, 1995, Pages 7-18

  Song, Cai ^a   Leonard, B E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

antidepressants; antihistamine; Depression; IL 2; immunological parameters; JO 1784; NPY; olfactory bulbectomy; thymopeptides

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTERONE; DESIPRAMINE; FLUVOXAMINE; INTERLEUKIN 2; LITHIUM; NEUROPEPTIDE Y; SERTRALINE; TERFENADINE;

ANIMAL EXPERIMENT; BEHAVIOR; CELL PROLIFERATION; DEPRESSION; DOPAMINERGIC SYSTEM; HUMAN; HYPERACTIVITY; IMMUNE SYSTEM; LYMPHOCYTE; NEUTROPHIL; NONHUMAN; NORADRENERGIC SYSTEM; OLFACTORY BULBECTOMY; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0028938794     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.470100103     Document Type: Review

References (131)

1. The state of leucocyte adhesiveness/aggregation in the peripheral blood: a new and independent marker of mental stress
2. Hypercortisolemia and hippocampal changes in depression
3. Changes of phagocytic biological rhythm by reduction of circadian times
4. The basis for amine hypotheses in affective disorder: a critical evaluation
5. Release of multiple hormones by a direct action of interleukin‐l on pituitary cells
6. Immunoregulatory feedback between interleukin‐l and glucocorticoid hormones
7. Etho experimental approaches to the biology of emotions
8. Effects of thymectomy on productive function and behaviour
9. Grief and mourning in infancy and early childhood
10. Corticosterone, choline acetyltransferase and noradrenaline levels in olfactory bulbectomised rats in relation to changes in passive avoidance acquisition and open field activity
11. Olfactory bulbectomy: neural structures involved in irritability and aggression in the male rat
12. Depression, immunocopetence, and prostaglandins of the E series
13. Facilitation of avoidance learning in anosmic rats by amitriptyline
14. Indigenous brain norepinephrine levels following bilateral olfactory bulb ablation
15. Effects of olfactory bulbectomy and domicile on stress induced corticosterone release in the rat
16. Olfactory projection system, drug and behaviour: a review
17. Absence of relationship between lymphocyte count, basal blood cortisol or response to dexamethasone suppression test in major depressed patients
18. Functional assessment and partial characterization of [3H](+)‐pentazocine binding sites on cells of the immune system
19. Neuroendocrine regulation in depressed patients
20. Basal plasma corticosterone level after bilateral selective lesions of the olfactory pathways in the rat
21. Thymosins and other thymic hormones
22. The anatomy of neuropeptide Y containing neurons in rat brain
23. Psychotomimetic effects and sigma ligands
24. Impaired mitogen‐induced lymphocyte responses and the hypothalamic‐pituitary‐adrenal axis in depressive disorders
25. Ambiguity and controversy: An introduction
26. Presynaptic alphareceptor subsensitivity after long term antidepressant treatment
27. Acceleration of beta‐receptor desensitization in combined administration of antidepressants and phenoxybenzamine
28. Immunological significance of in vitro lymphocyte responses
29. Peripheral white blood cells and HPA axis neurohormones in major depression
30. Neutrophilia and lymphopenia in major mood disorders
31. Mitogen‐stimulated lymphocyte proliferation and pituitary hormones in major depression
32. Distribution of neuropeptide Y‐like immunoreactivity in the rat central nervous system: I. Radioimmunoassay and chromatographic characterisation
33. Strss‐mechanisms of immunosuppression
34. Nervous system‐immune system interaction: a review
35. Psychoneuroimmunology for the psychoneuroendocrinologist: a review of animal studies of nervous system‐immune system interactions
36. Non‐sensory involvement of the olfactory bulbs in the mediation of social behaviour
37. Olfactory system damage and brain catecholamines in the rat
38. Olfactory regulation of maternal behaviour in rats: II. Effects of peripherally induced anosmia and lesions of the lateral olfactory tract in pup‐induced killing
39. Antibody response to cholera vaccine: Differences between depressed, schizophrenic, and normal subjects
40. Effect of bilateral olfactory bulbectomy in the rat, alone or in combination with antidepressants, on the learned immobility model of depression
41. Vulnerability and immune response
42. The role of brain 5‐hydroxytryptamine in the hyperactivity produced by rats in lithium and monoamine oxidase inhibitors
43. Central neuropeptide Y and the sigma ligand, JO 1784, reverse corticotropin‐release factorinduced inhibition of gastric acid secretion in rats
44. Neuropeptide Y and sigma ligand (JO 1784). suppress stress‐induced colonic motor disturbances in rats through sigma and cholecystokinin receptors
45. α 1‐Acid glycoprotein in major depressive and eating disorders
46. Antidepressant drugs increase the concentration of neuropeptide Y (NPY)‐like immunoreactivity in the rat's brain
47. Treatment of depression with drugs
48. Reduction of immune function in life stress and depression
49. The olfactory bulbectomized rat as a model of depression
50. Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat
51. Production of interferon‐α and β by leukocytes from patients with schizophrenia
52. Mother‐infant relations in monkeys and humans
53. Histamine‐ and stress‐induced secretion of ACTH and β‐endorphin: involvement of corticotropin‐releasing hormone and vasopressin
54. The role of corticotropin‐releasing factor in behavioural responses to stress
55. Impaired lymphocyte function in depressive illness
56. Depression, cortisol, and immune function
57. Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls
58. Depression, urinary free cortisol excretion and lymphocyte function
59. Lymphocyte subsets in patients with major depression: preliminary findings
60. The olfactory control of meal pattern in rats
61. Novel antipsychotic drugs share high affinity for δ receptors
62. Cortical concentrations of corticotrophinreleasing hormone and its receptor in Alzheimer type dementia and major depression
63. Neurochemical and behavioural aspects of olfactory bulbectomy in the rat
64. Anatomical, physiological and behavioural aspects of olfactory bulbectomy in the rat
65. The olfactory bulbectomized rat as a model of depression
66. Pharmacology of new antidepressants
67. Neurotransmitter receptors, endocrine responses and the biological substrates of depression: a review
68. From animals to man: advantages, problems and pitfalls of animal models in psychopharmacology
69. Stress and the immune system: immunological aspects of depressive illness
70. Neutrophil chemotaxis, phagocytosis, and superoxide release in depressive‐illness
71. Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression
72. Effects of bilateral lesions of the olfactory bulbs of rats on measures of learning and motivation
73. Effect of nonsedating histamine H1‐antagonist on EEG activity and behaviour in the cat
74. Outcome after thymectomy for myasthenia‐gravis–a retrospective review
75. Interleukin‐1 β stimulates corticotropin‐releasing hormone (CRH). and adrenocorticotropin (ACTH). release by rat adrenal gland in vitro
76. Neutrophil and monocyte phagocytosis in depressed patients
77. Biobehavioural models of depression in monkey
78. Cortisol determination and the dexamethasone suppression test, a review
79. Depression, adrenal steroids, and the immune system
80. Involvement of sigma receptors in shizophrenic syndromes
81. Psychoses in 3 cases with myasthenia‐gravis and thymoma proposal of a paraneoplastic autoimmune neuropsychiatric syndrome
82. Effects of stress on the secretion of corticosterone in the bulbectomized rat model of depression
83. Interleukin‐1 (IL‐1). stimulates the release of corticortropin‐releasing factor (CRF). from superfused rat independently of the histamine mechanism
84. Depressed neutrophil phagocytosis in the rat following olfactory bulbectomy reversed by chronic desipramine treatment
85. β‐adrenergic receptor function in affective illness
86. Olfactory bulb removal: effects on brain norepinephrine
87. Effects of bulbectomisation, strain and gentling on emotionality and exploratory behaviour in rats
88. Lifetime prevalence of specific psychiatric disorders in three sites
89. JO1784, a potent and selective legend for rat and mouse brain sigma sites
90. Sleep wakefulness rhythms in the olfactory bulb lesioned rat
91. The catecholamine hypothesis of affective disorders: a review of supporting evidence
92. Lymphocyte function in major depressive disorder
93. Depression and immunity
94. Hypothalamic‐pituitary‐adrenal axis activity in depressive illness, its relationship to classification
95. Clinical aspects of lithium in psychiatry
96. Learned helplessness in the rat: Reversibility, time course and immunization
97. The role of the olfactory system in avoidance learning and activity
98. The macrophage theory of depression
99. Effect of thymopeptides on the behaviour and some immunological responses in the olfactory bulbectomized rats
100. The effects of chronic lithium chloride administration on some behavioural and immunological changes in the bilaterally olfactory bulbectomized rat
101. Serotonin reuptake inhibitors reverse the impairments in behaviour, neurotransmitter and immune functions in the olfactory bulbectomized rat
102. An acute phase protein response in the olfactory bulbectomized rate: effect of sertraline treatment
103. Is the state of leukocyte adhesiveness/aggregation an immune marker of stress in the olfactory bulbectomized rat?
104. Behaviour, lymphocyte activity and serum corticosterone level in olfactory bulbectomized rats following chronic desipramine treatment
105. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls
106. Review of the pharmacology of existing antidepressants
107. Stress and immunomodulation: the role of depression and neuroendocrine function
108. Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: molecular approaches to an understanding of affective disorders
109. Unsuppression of cortisol in depression and immune function
110. Lymphocyte subpopulations in depressed elderly women
111. Histamine leukocytosis. I. Effect of histamine on peripheral leukocyte counts
112. Searching‐waiting strategy: a candidate for an evolutionary model of depression?
113. Effects of psychotropic drugs on the behaviour and neurochemistry of olfactory bulbectomized rats
114. Central administration of interleukin‐1β increases norephinephrine turnover in the spleen
115. Behavioural depression produced by uncontrollable stressor: relationship to noreprinephrine, dopamine, and serotonin levels in various regions of rat brain
116. Depression and immunocompetence: a review of the literature
117. Increased levels of neuropeptide‐Y immunoreactivity in rat brain limbic structures following antidepressant treatment. (Abstract)
118. Reduced neuropeptide Y concentrations in suicide brain
119. Altered brain neuropeptide function in psychiatric illness–with special emphasis on NPY and CRF in major depression. Proceedings of C.I.N.P., 15th Congress
120. Possible relationship between Neuropeptide Y (NPY). and major depression: evidence from human and animal studies
121. Peripheral alpha adrenergic activity in the affective disorders
122. A review of the biochemical and neuropharmacological actions of lithium
123. Cytokine‐specific central monoamine alteration induced by interleukin‐1,‐2 and ‐6